Genome editing in cancer: Challenges and potential opportunities.
CRISPR/Cas systems
Cancer therapy
Genome editing
Off-target activity
Journal
Bioactive materials
ISSN: 2452-199X
Titre abrégé: Bioact Mater
Pays: China
ID NLM: 101685294
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
received:
01
06
2022
revised:
21
08
2022
accepted:
24
08
2022
entrez:
3
10
2022
pubmed:
4
10
2022
medline:
4
10
2022
Statut:
epublish
Résumé
Ever since its mechanism was discovered back in 2012, the CRISPR/Cas9 system have revolutionized the field of genome editing. While at first it was seen as a therapeutic tool mostly relevant for curing genetic diseases, it has been recently shown to also hold the potential to become a clinically relevant therapy for cancer. However, there are multiple challenges that must be addressed prior to clinical testing. Predominantly, the safety of the system when used for
Identifiants
pubmed: 36185740
doi: 10.1016/j.bioactmat.2022.08.013
pii: S2452-199X(22)00356-5
pmc: PMC9483578
doi:
Types de publication
Journal Article
Langues
eng
Pagination
394-402Informations de copyright
© 2022 The Authors.
Déclaration de conflit d'intérêts
D.P. declares the following competing financial interest(s): D.P. receives licensing fees (to patents on which he was an inventor) from, invested in, consults (or on scientific advisory boards or boards of directors) for, lectured (and received a fee) or conducts sponsored research at TAU for the following entities: ART Biosciences, BioNtech SE., Kernal Biologics, Merck, Newphase Ltd., NLC Pharma Ltd., NeoVac Ltd., Roche, SirTLabs Corporation, Teva Pharmaceuticals Inc. D.B. declares no competing financial interests.
Références
Nat Biotechnol. 2015 Feb;33(2):187-197
pubmed: 25513782
Nat Biotechnol. 2020 Jul;38(7):824-844
pubmed: 32572269
Methods. 2021 Mar;187:77-91
pubmed: 32315755
Beilstein J Org Chem. 2021 Apr 26;17:891-907
pubmed: 33981364
J Biol Chem. 2020 Apr 24;295(17):5538-5553
pubmed: 32161115
Nucleic Acids Res. 2020 Sep 4;48(15):8601-8616
pubmed: 32687187
Cancers (Basel). 2022 Mar 21;14(6):
pubmed: 35326738
Adv Drug Deliv Rev. 2022 Mar;182:114113
pubmed: 35063535
Nat Nanotechnol. 2022 Jul;17(7):777-787
pubmed: 35551240
Hum Gene Ther. 2015 May;26(5):257-65
pubmed: 25807962
Science. 2019 Apr 19;364(6437):286-289
pubmed: 31000663
Cell Rep. 2021 Jun 1;35(9):109207
pubmed: 34077734
Nat Nanotechnol. 2019 Oct;14(10):974-980
pubmed: 31501532
Biomaterials. 2020 Nov;258:120275
pubmed: 32798741
Mol Biotechnol. 2022 Apr;64(4):355-372
pubmed: 34741732
Nature. 2016 Jan 28;529(7587):490-5
pubmed: 26735016
Int J Mol Sci. 2022 Mar 01;23(5):
pubmed: 35269876
Nature. 2015 Apr 9;520(7546):186-91
pubmed: 25830891
Nature. 2014 Oct 16;514(7522):380-4
pubmed: 25119044
Cell. 2015 Oct 22;163(3):759-71
pubmed: 26422227
Nat Biotechnol. 2021 Dec;39(12):1514-1515
pubmed: 34773124
CRISPR J. 2022 Feb;5(1):7-18
pubmed: 35076280
Nat Commun. 2021 May 24;12(1):3042
pubmed: 34031394
Mol Cell. 2015 May 21;58(4):575-85
pubmed: 26000843
Elife. 2016 Nov 02;5:
pubmed: 27805569
Cells. 2021 Nov 29;10(12):
pubmed: 34943856
ACS Synth Biol. 2019 May 17;8(5):1079-1088
pubmed: 31039307
Cell Rep. 2014 Nov 20;9(4):1219-27
pubmed: 25456124
Mol Ther Methods Clin Dev. 2020 May 04;17:1097-1107
pubmed: 32478125
Adv Drug Deliv Rev. 2020;154-155:176-186
pubmed: 32659256
CA Cancer J Clin. 2022 Jan;72(1):7-33
pubmed: 35020204
ACS Synth Biol. 2019 Jul 19;8(7):1583-1589
pubmed: 31290648
Annu Rev Genet. 2006;40:363-83
pubmed: 16895466
Sci Transl Med. 2021 Jun 16;13(598):
pubmed: 34135108
Nat Nanotechnol. 2018 Mar;13(3):214-219
pubmed: 29379205
Acta Pharm Sin B. 2018 Mar;8(2):165-177
pubmed: 29719777
Cell. 2020 Dec 10;183(6):1650-1664.e15
pubmed: 33125898
Nat Biotechnol. 2013 Sep;31(9):827-32
pubmed: 23873081
Trends Biotechnol. 2013 Jul;31(7):397-405
pubmed: 23664777
N Engl J Med. 2019 Mar 7;380(10):947-959
pubmed: 30855744
Nat Rev Genet. 2020 Apr;21(4):255-272
pubmed: 32042148
Nat Biotechnol. 2022 Apr;40(4):539-545
pubmed: 34711989
Cell. 2022 Jan 20;185(2):250-265.e16
pubmed: 35021064
Nat Biomed Eng. 2018 Jul;2(7):497-507
pubmed: 30948824
Nat Biotechnol. 2022 Jun 30;:
pubmed: 35773341
Mol Ther Methods Clin Dev. 2018 Jun 15;10:105-112
pubmed: 30073181
Quant Biol. 2014 Jun;2(2):59-70
pubmed: 25722925
J Control Release. 2022 Feb;342:362-371
pubmed: 35041904
Biomaterials. 2021 May;272:120793
pubmed: 33836291
Bioeng Transl Med. 2021 Mar 20;6(2):e10213
pubmed: 33786376
Genome Biol. 2020 Nov 17;21(1):279
pubmed: 33203452
Mol Ther Methods Clin Dev. 2017 Apr 19;5:153-164
pubmed: 28497073
Annu Rev Pharmacol Toxicol. 2016;56:163-90
pubmed: 26566154
Nat Methods. 2017 Jun;14(6):607-614
pubmed: 28459458
Nat Biotechnol. 2022 May;40(5):731-740
pubmed: 34887556
Annu Rev Biochem. 2014;83:409-39
pubmed: 24606144
Curr Opin Pharmacol. 2015 Oct;24:105-12
pubmed: 26342909
Nat Commun. 2021 Dec 13;12(1):7233
pubmed: 34903741
Nature. 2017 Oct 12;550(7675):280-284
pubmed: 28976959
J Control Release. 2019 Nov 10;313:33-41
pubmed: 31634546
Genetics. 2002 Jul;161(3):1169-75
pubmed: 12136019
Nature. 2019 Dec;576(7785):149-157
pubmed: 31634902
Macromol Biosci. 2019 Jul;19(7):e1900162
pubmed: 31173461
Nat Biomed Eng. 2017;1:889-901
pubmed: 29805845
Nature. 2017 Nov 23;551(7681):464-471
pubmed: 29160308
Pharmaceutics. 2021 Oct 13;13(10):
pubmed: 34683969
Cell. 2013 Feb 28;152(5):1173-83
pubmed: 23452860
Nat Med. 2022 Jul;28(7):1372-1376
pubmed: 35668177
Science. 2021 Aug 20;373(6557):882-889
pubmed: 34413232
Cell. 2013 Jul 18;154(2):442-51
pubmed: 23849981
Cancers (Basel). 2022 Feb 14;14(4):
pubmed: 35205694
Nat Biotechnol. 2020 Jul;38(7):883-891
pubmed: 32433547
Front Cell Dev Biol. 2021 Jul 27;9:677587
pubmed: 34386490
Nature. 2016 Apr 20;533(7603):420-4
pubmed: 27096365
Science. 2016 Sep 16;353(6305):
pubmed: 27492474
Nat Commun. 2018 Oct 29;9(1):4493
pubmed: 30374059
J Pharm Sci. 2020 Jan;109(1):62-67
pubmed: 31589876
Sci Adv. 2020 Nov 18;6(47):
pubmed: 33208369
Acta Pharm Sin B. 2021 Aug;11(8):2150-2171
pubmed: 34522582
ACS Synth Biol. 2021 May 21;10(5):964-971
pubmed: 33930275
Science. 2016 Jan 1;351(6268):84-8
pubmed: 26628643
Cell. 2014 Jun 5;157(6):1262-1278
pubmed: 24906146
Science. 2012 Aug 17;337(6096):816-21
pubmed: 22745249
Nat Biotechnol. 2014 Jun;32(6):577-582
pubmed: 24770324
Nature. 2022 Mar;603(7900):343-347
pubmed: 35236982
Nat Commun. 2019 Mar 8;10(1):1136
pubmed: 30850590
Nat Biotechnol. 2015 Sep;33(9):985-989
pubmed: 26121415
Nature. 2017 Oct 19;550(7676):407-410
pubmed: 28931002
Nat Biotechnol. 2013 Sep;31(9):822-6
pubmed: 23792628
ACS Appl Mater Interfaces. 2020 Dec 23;12(51):57362-57372
pubmed: 33301289
Proc Natl Acad Sci U S A. 2016 Jan 5;113(1):E16-22
pubmed: 26699502
Biotechnol J. 2014 Nov;9(11):1402-12
pubmed: 25186301
J Clin Invest. 2014 Oct;124(10):4154-61
pubmed: 25271723
PLoS One. 2015 Mar 23;10(3):e0118472
pubmed: 25799489
Front Pharmacol. 2021 Feb 03;12:601626
pubmed: 33613290
Future Virol. 2018 Jul;13(7):475-482
pubmed: 30245733
Nat Genet. 2021 Jun;53(6):895-905
pubmed: 33846636
Nucleic Acid Ther. 2018 Oct;28(5):285-296
pubmed: 30088967
Nat Med. 2019 Feb;25(2):249-254
pubmed: 30692695
Biomater Sci. 2018 May 29;6(6):1592-1603
pubmed: 29725684
DNA Repair (Amst). 2016 Aug;44:6-16
pubmed: 27261202
J Control Release. 2022 Feb;342:345-361
pubmed: 35026352
Nat Methods. 2017 Jun;14(6):600-606
pubmed: 28459459
Signal Transduct Target Ther. 2021 Dec 3;6(1):411
pubmed: 34857736
Nat Biomed Eng. 2021 Feb;5(2):144-156
pubmed: 33398131